Introduction Canakinumab (CAN), a selective, human anti-IL-1b monoclonal antibody is approved for SJIA in over 30 countries. Efficacy and safety of CAN over 12 weeks have been demonstrated in 2 phase III trials [1]. Out of these trials >60% of the pts received a previous biologic and were switched to CAN due to lack of efficacy or for safety reasons, and may be more refractory to another biolog...

Background Granulocyte-monocyte apheresis has been proposed for the treatment of ulcerative colitis, although it is limited by costs and variability of results. Aim To assess effectiveness of granulocyte-monocyte apheresis in patients with steroid-dependent, azathioprine-intolerant/resistant moderate ulcerative colitis. Methods Consecutive patients fulfilling inclusion criteria were prospec...

BACKGROUND Esophageal Crohn's disease is reported as a rare manifestation, although its prevalence may be underestimated because upper endoscopies are not routinely performed in asymptomatic adults. Tofacitinib, an oral janus kinase inhibitor, is a new biologic that has shown promise in the treatment of ulcerative colitis and may be effective in the treatment of Crohn's disease according to pha...

In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn's disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn's disease, we review the profile of the a...

Pharmaceutical companies are increasingly focused on biologic therapeutics rather than biochemical, chemical and radiological compounds for many cancer treatments. Biologic therapeutics only target and destroy specific cancer cells, thus preventing damage to surrounding, healthy cells and reducing unwanted cytotoxic events. The most prominent and successful example is Rituximab (Rituxan®; Roche...

background and objective: in this study, we explored expression rate, some biomarkers affecting the prognosis of the breast carcinoma, and the relationship between these markers and clinicopathologic features of the disease as well as the relationship between each of these markers through a tissue array technique. materials and methods: this study was an observational and cross-sectional study....

TNF blockade therapy has substantially advanced the treatment of peripheral spondyloarthritides but revolutionised the treatment of severe ankylosing spondylitis. The capacity of biologic treatment to improve dramatically symptoms and quality of life in patients with spinal disease is undoubted, although important questions remain. Notable amongst these are concerns about skeletal disease modif...

OBJECTIVE To review the impact of biologic therapies on commercial and government payers. SUMMARY Biologic agents, a mainstay in the treatment of cancer and immunopathologic conditions, are being used for an expanding number of indications, and new agents are being developed for use in many other diseases. These biologic agents have the potential to improve patient quality of life and the ove...

The article presents updated guidelines developed by the American College of Rheumatology and Association Hip Knee Surgeons on perioperative treatment patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic juvenile idiopathic arthritis systemic lupus erythematosus undergoing elective total hip or knee arthroplasty. use anti-rheumatic drug therapy, including traditional disease-mo...

Tumor necrosis factor α (TNF-α) plays a central role in the pathophysiology of Alzheimer's disease (AD). Food and Drug Administration-approved biologic TNF-α inhibitors are thus a potential treatment for AD, but they do not cross the blood-brain barrier. In this short review, we discuss the involvement of TNF-α in AD, challenges associated with the development of existing biologic TNF-α inhibit...